Dr. Arteaga on Key Takeaway Points From the 2012 SABCS

Video

Carlos L. Arteaga, MD, from Vanderbilt-Ingram Cancer Center, describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

Carlos L. Arteaga, MD, director of the Breast Cancer Program at the Vanderbilt-Ingram Cancer Center and the co-director of the San Antonio Breast Cancer Symposium (SABCS), describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

For practicing oncologists, who see patients five days a week, Arteaga hopes that SABCS will provide relevant information on new trends in breast cancer care. If patterns in care need revised, SABCS may provide essential information to induce skepticism and foster progress.

SABCS hopes to provide the latest information on targeted therapies in breast cancer, for clinical investigators. This information is vital for making enlightened decisions on future research, in the following year.

Arteaga hopes scientists will leave the symposium with a better understanding of the key questions in breast cancer biology. This meeting provides insight into clinically relevant areas that will likely benefit this group of individuals a great deal.

<<<

View coverage from the 2012 SABCS

Related Videos
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.